Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06963463 · ClinicalTrials.gov registry record · NA

Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression (TranS-C+BL)

A NA study of Depression and Sleep, sponsored by University of Pittsburgh.

Recruiting
Registry status
NA
Development phase
90
Enrollment target
2
Study locations

NCT06963463: Recruiting NA study of Depression and Sleep, sponsored by University of Pittsburgh.

NCT06963463 is a NA study of Depression and Sleep that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 90 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06963463, a NA study of Depression and Sleep, is actively recruiting participants, sponsored by University of Pittsburgh.

RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to adapt a sleep intervention for individuals representative of all demographic groups, including those who are at the highest risk for suicidal behavior. Sleep difficulties are a promising target for youth with suicidal thoughts and behavior to focus on as a prevention measure. We aim to increase intervention acceptability and impact by adapting it for the adolescent populations at highest risk for suicidal thoughts and behavior. The research project will compare Transdiagnostic Sleep and Circadian Intervention (TranS-C), an evidence based, modularized intervention that targets a range of sleep difficulties to a treatment as usual or control condition including providing weekly sleep feedback reports from data entered into a daily sleep diary and from wearing a sleep sensing, actigraphy watch. Participants in both conditions (TranS-C vs. Sleep Feedback) will wear an actigraphy sleep watch that monitors sleep, and complete daily sleep diaries via smartphone or email. Participants in the TranS-C condition will also wear bright light (BL) and blue blocking glasses each day as well as attend weekly or biweekly sessions with a Sleep Therapist. The sleep therapist will review sleep feedback during sessions.

Primary Outcome

Feasibility of interventions as by measured by the mean of number of sessions attended. Local study documents are used to track each session that was completed.

Interventions

  • BEHAVIORAL TranS-C
  • BEHAVIORAL Sleep Feedback

Study Locations (2)

Pennsylvania

  • Childrens Hospital of Philadelphia - Philadelphia
  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-05-06
Est. Completion 2027-07-31
Phase NA
University of Pittsburgh

1,238 total trials

What NCT06963463 shows while recruiting

NCT06963463 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (89% lower).

The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which TranS-C is the first listed.

NCT06963463 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06963463 about?

NCT06963463 is a clinical study titled "Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression (TranS-C+BL)". The goal of this clinical trial is to adapt a sleep intervention for individuals representative of all demographic groups, including those who are at the highest risk for suicidal behavior. Sleep difficulties are a promising target for youth with suicidal thoughts and behavior to focus on as a preve...

What is the current status of trial NCT06963463?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2025-05-06. Estimated completion is 2027-07-31.

What conditions does trial NCT06963463 study?

This clinical trial studies the following conditions: Depression, Sleep, Suicide, Sleep Disturbance.

What interventions are being tested in trial NCT06963463?

The interventions under investigation include: TranS-C (BEHAVIORAL), Sleep Feedback (BEHAVIORAL).

Who is sponsoring clinical trial NCT06963463?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06963463 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06963463's enrollment target sits among peer trials

90 357th of 679 higher than 320 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT06963463, the US trial registry maintained by the National Library of Medicine. NCT06963463 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.